Insilico reports early mesothelioma responses with AI-designed TEAD inhibitor ISM6331

Insilico Medicine reported preliminary Phase I results of ISM6331, an AI-designed oral pan-TEAD inhibitor, showing promising response rates and disease control in mesothelioma patients without dose-limiting toxicity. The drug has FDA orphan and Fast Track designations, with ongoing dose escalation and plans for a Phase IIa trial.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 26 Oct 2026 and 27 Oct 2026.